Hosted on MSN1d
Island Pharmaceuticals starts phase 2b dengue trialIsland Pharmaceuticals has commenced its phase 2b clinical trial of lead drug ISLA-101 – for potentially treating dengue ...
Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA) CEO and managing director David Foster to get the short end of the long story on the company’s latest news.
Stockhead on MSN1d
Health Check: Which stock just dumped 19% on earnings downgrade?Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...
Island Pharmaceuticals pioneers antiviral drug development to combat infectious diseases worldwide. Opsin Biotherapeutics innovates in vision restoration therapies, transforming treatment ...
GenrAb leads in the development of next-gen antibody therapeutics, addressing critical medical challenges. Island Pharmaceuticals pioneers antiviral drug development to combat infectious diseases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback